ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Metformin

Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.

Drug pageMetformin: every studyMany companies study it; this page follows only the 215 they lead. All 1,290 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 9, 2005215 company-led studies, 7 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only290 open or runningphase 3since Nov 9, 2005Nov 9, 2005none ahead
Merckits history only190 open or runningphase 4since Oct 9, 2009Feb 15, 2005none ahead
Sanofiits history only160 open or runningphase 4since Jul 28, 2006Sep 30, 2002none ahead
GlaxoSmithKlineits history only140 open or runningphase 4since Oct 17, 2005Sep 3, 2003none ahead
Takeda120 open or runningphase 4since Sep 17, 2008Jul 30, 2008none ahead
Merck KGaA, Darmstadt, Germanyits history only90 open or runningphase 4since Dec 30, 2011Dec 30, 2011none ahead
Teva Pharmaceutical Industriesits history only90 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatrisits history only80 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
ADIUMits history only70 open or runningno phasesince Jun 3, 2026Jun 3, 2026none ahead
LG Chemits history only70 open or runningphase 3since Feb 6, 2013Aug 22, 2011none ahead

Also a collaborator on its studies: Parexel, PT Pharma Metric Labs, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly and Merck, S.L., Spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 30, 2008First study: phase 3 study in Diabetes MellitusFirst studyNCT00727857 · 600 enrolled · United States, Chile, Mexico and more
  2. Sep 17, 2008Phase 4 study in Diabetes MellitusNCT00754403 · 312 enrolled
  3. Oct 8, 20082 phase 3 studies in Diabetes MellitusNCT00772174, NCT00770653
  4. Oct 8, 20082 phase 4 studies in Diabetes MellitusNCT00770835, NCT00770445
  5. Dec 1, 2009Phase 3 study in Diabetes Mellitus, Type 2NCT01023581 · 784 enrolled · United States, Czech Republic, Hungary and more
  6. Feb 1, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01289119 · 506 enrolled · China, Hong Kong, Taiwan
  7. Mar 16, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01318109 · 288 enrolled
  8. Jun 26, 2013Phase 3 study in Diabetes MellitusNCT01890122 · 647 enrolled · China, Korea, Republic of, Malaysia and more
  9. Oct 24, 2013Phase 4 study in Diabetes Mellitus, Type 2NCT01972724 · 114 enrolled · Korea, Republic of
  10. Feb 19, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02068443 · 374 enrolled · Japan

TargetBeta

“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

All 12 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02068443Diabetes Mellitus, Type 2 · Japan3CompletedFeb 2015374
NCT01972724Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedOct 17, 2016114
NCT01890122Diabetes Mellitus · China, Korea, Republic of, Malaysia and more3CompletedSep 2015647
NCT01318109Diabetes Mellitus, Type 23CompletedApr 2009288
NCT01289119Diabetes Mellitus, Type 2 · China, Hong Kong, Taiwan3CompletedDec 2011506
NCT01023581Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more3CompletedJun 2011784
NCT00770653Diabetes Mellitus · Germany3CompletedMay 2009305
NCT00770445Diabetes Mellitus · Germany4CompletedJul 2010121
NCT00772174Diabetes Mellitus3CompletedFeb 2008418
NCT00770835Diabetes Mellitus · Italy4CompletedMay 201139
NCT00754403Diabetes Mellitus4CompletedOct 2006312
NCT00727857Diabetes Mellitus · United States, Chile, Mexico and more3CompletedAug 2008600

How it is read

Names in the registry

  • “Metformin”, 95 entries
  • “metformin”, 33 entries
  • “Metformin XR”, 11 entries
  • “Fenofibrate /Metformin”, 6 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: EFB0027.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.